Subtopic Deep Dive
FGF23 in Chronic Kidney Disease Mineral Bone Disorder
Research Guide
What is FGF23 in Chronic Kidney Disease Mineral Bone Disorder?
FGF23 in Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD) refers to elevated fibroblast growth factor 23 levels in CKD stages 3-5D that promote phosphaturia, secondary hyperparathyroidism, and cardiovascular risks.
FGF23 rises early in CKD, suppressing 1,25-dihydroxyvitamin D and parathyroid hormone initially but contributing to left ventricular hypertrophy and mortality later (Shalhoub et al., 2012, 400 citations). KDIGO guidelines highlight FGF23 as a biomarker in CKD-MBD management (KDIGO, 2017, 1854 citations). Over 50 papers in the provided list link FGF23 to vascular calcification and fibrosis.
Why It Matters
Elevated FGF23 associates with cardiovascular events and mortality in CKD patients, serving as a biomarker for CKD-MBD progression (Shalhoub et al., 2012). Neutralization studies show FGF23 blockade improves hyperparathyroidism but raises mortality risk, guiding therapeutic development (Shalhoub et al., 2012). FGF23 excess drives vascular calcification independently of phosphate, impacting dialysis outcomes (Yamada and Giachelli, 2016). Phosphorus restriction trials target FGF23 to reduce CKD morbidity (Isakova et al., 2010).
Key Research Challenges
FGF23 Neutralization Mortality Risk
FGF23 blockade ameliorates hyperparathyroidism but unexpectedly increases mortality in CKD models (Shalhoub et al., 2012). Balancing phosphaturic benefits against cardiovascular harm remains unresolved. Clinical translation requires safer inhibitors.
Vascular Calcification Mechanisms
FGF23 promotes medial calcification via Klotho-independent pathways in CKD-MBD (Yamada and Giachelli, 2016). Early CKD-MBD stimulates calcification before overt hyperphosphatemia (Fang et al., 2013). Separating FGF23 effects from phosphate needs advanced models.
Klotho-FGF23 Dysregulation
Soluble Klotho decline correlates with arterial stiffness and amplifies FGF23 toxicity in CKD (Kitagawa et al., 2013). Restoring Klotho expression faces delivery challenges (Zou et al., 2018). Inflammation and iron status modulate this axis unpredictably.
Essential Papers
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
Unknown · 2017 · Kidney International Supplements · 1.9K citations
FGF23 neutralization improves chronic kidney disease–associated hyperparathyroidism yet increases mortality
Victoria Shalhoub, Edward Shatzen, Sabrina C. Ward et al. · 2012 · Journal of Clinical Investigation · 400 citations
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is associated with secondary hyperparathyroidism (HPT) and serum elevations in the phosphaturic hormone FGF23, which may be maladaptive an...
Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences
Sara Panizo, Laura Martínez‐Arias, Cristina Alonso‐Montes et al. · 2021 · International Journal of Molecular Sciences · 330 citations
Fibrosis is a process characterized by an excessive accumulation of the extracellular matrix as a response to different types of tissue injuries, which leads to organ dysfunction. The process can b...
Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho
Shunsuke Yamada, Cecilia M. Giachelli · 2016 · Bone · 308 citations
Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update
Stefanos Roumeliotis, Francesca Mallamaci, Carmine Zoccali · 2020 · Journal of Clinical Medicine · 249 citations
The vascular endothelium is a dynamic, functionally complex organ, modulating multiple biological processes, including vascular tone and permeability, inflammatory responses, thrombosis, and angiog...
Vascular calcification in chronic kidney disease: an update
Georg Schlieper, Leon J. Schurgers, Vincent Brandenburg et al. · 2015 · Nephrology Dialysis Transplantation · 238 citations
Cardiovascular calcification is both a risk factor and contributor to morbidity and mortality. Patients with chronic kidney disease (and/or diabetes) exhibit accelerated calcification of the intima...
Klotho, Aging, and the Failing Kidney
Sarah Buchanan, Emilie Combet, Peter Stenvinkel et al. · 2020 · Frontiers in Endocrinology · 223 citations
Klotho has been recognized as a gene involved in the aging process in mammals for over 30 years, where it regulates phosphate homeostasis and the activity of members of the fibroblast growth factor...
Reading Guide
Foundational Papers
Start with Shalhoub et al. (2012, 400 citations) for FGF23 neutralization in CKD-MBD core mechanisms and paradoxes. Follow with Fang et al. (2013, 212 citations) on early vascular calcification triggers. KDIGO 2017 (1854 citations) provides clinical context.
Recent Advances
Yamada and Giachelli (2016, 308 citations) details FGF23-Klotho in calcification. Panizo et al. (2021, 330 citations) covers fibrosis consequences. Roumeliotis et al. (2020, 249 citations) updates endothelial dysfunction links.
Core Methods
Rodent CKD models with FGF23 antibodies (Shalhoub et al., 2012). Phosphorus binder trials (Isakova et al., 2010). Serum biomarker correlations with imaging for calcification (Yamada and Giachelli, 2016; Fang et al., 2013).
How PapersFlow Helps You Research FGF23 in Chronic Kidney Disease Mineral Bone Disorder
Discover & Search
Research Agent uses searchPapers and exaSearch to find KDIGO 2017 guidelines (1854 citations) plus 50+ related papers on FGF23 in CKD-MBD. citationGraph reveals Shalhoub et al. (2012) as a hub connecting hyperparathyroidism and mortality studies. findSimilarPapers expands from Yamada and Giachelli (2016) to map vascular calcification clusters.
Analyze & Verify
Analysis Agent applies readPaperContent to extract FGF23 neutralization data from Shalhoub et al. (2012), then verifyResponse with CoVe checks claims against KDIGO 2017. runPythonAnalysis performs meta-analysis on citation counts and FGF23 levels from 10 papers using pandas. GRADE grading scores evidence quality for therapeutic targeting.
Synthesize & Write
Synthesis Agent detects gaps in FGF23-Klotho interventions post-Shalhoub 2012 via contradiction flagging. Writing Agent uses latexEditText and latexSyncCitations to draft CKD-MBD review sections citing Fang et al. (2013). latexCompile generates polished manuscripts; exportMermaid visualizes FGF23-phosphate-Klotho pathways.
Use Cases
"Analyze FGF23 levels vs mortality risk in CKD-MBD cohorts from 10 papers"
Analysis Agent → runPythonAnalysis (pandas meta-analysis on extracted FGF23/mortality data from Shalhoub 2012, Fang 2013) → statistical plots and correlation outputs for researcher.
"Draft LaTeX review on FGF23 neutralization paradoxes citing Shalhoub 2012"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (KDIGO 2017, Yamada 2016) → latexCompile → camera-ready PDF.
"Find code for modeling FGF23-Klotho interactions in CKD"
Research Agent → paperExtractUrls (from Rowe 2012 pathway paper) → paperFindGithubRepo → githubRepoInspect → Python scripts for mineral metabolism simulations.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ FGF23-CKD papers: searchPapers → citationGraph → GRADE all via DeepScan checkpoints. Theorizer generates hypotheses on FGF23-iron-inflammation links from Zou 2018 and Kitagawa 2013. DeepScan verifies Shalhoub 2012 mortality claims across datasets with CoVe.
Frequently Asked Questions
What defines FGF23's role in CKD-MBD?
FGF23 elevates early in CKD to induce phosphaturia but later drives secondary hyperparathyroidism, hypovitaminosis D, and cardiovascular risks (Shalhoub et al., 2012; KDIGO, 2017).
What are key methods studying FGF23?
Neutralization in rodent CKD models tests therapeutic potential (Shalhoub et al., 2012). Dietary phosphorus restriction and binders lower FGF23 in pilots (Isakova et al., 2010). Serum assays correlate FGF23 with calcification outcomes (Yamada and Giachelli, 2016).
What are seminal papers on FGF23 in CKD-MBD?
Shalhoub et al. (2012, 400 citations) shows neutralization benefits and risks. KDIGO 2017 (1854 citations) standardizes CKD-MBD guidelines including FGF23. Fang et al. (2013, 212 citations) links early CKD-MBD to calcification.
What open problems exist in FGF23-CKD research?
Resolving FGF23 neutralization's mortality paradox needs human trials (Shalhoub et al., 2012). Klotho restoration strategies lack efficacy data (Kitagawa et al., 2013). Inflammation-iron modulators of FGF23 require longitudinal studies.
Research Parathyroid Disorders and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching FGF23 in Chronic Kidney Disease Mineral Bone Disorder with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers